Item 1.01 Entry into a Material Definitive Agreement
As previously reported, vivoPharm
To complete the disposition of the Company's former vivoPharm business and to
resolve certain issues that have arisen with the Buyer, on
The above summary is not a complete description of the Agreement, and is qualified in its entirety by reference to the complete text of the document, which is filed as Exhibit 2.1 to this Current Report on Form 8-K and incorporated by reference in its entirety. The representations, warranties and covenants contained in the Agreement were made only as of specified dates for the purposes of the Agreement, were solely for the benefit of the parties to the Agreement, may be subject to qualifications and limitations agreed upon by such parties and were negotiated with the principal purpose of allocating risk between the parties, rather than establishing matters as facts.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 2.1* Share Purchase Agreement, datedMarch 13, 2023 , by and betweenVyant Bio, Inc. andSabine Brandt as trustee for theBrandt Family Trust 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
* We have omitted certain schedules and exhibits to this agreement in accordance
with Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or
exhibit will be furnished to the
© Edgar Online, source